Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Financials | Market Cap | ROE | ROA | ROCE | ROIC | D/E | Current Ratio | Gross Margin | Profit Margin | Operating Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $7.40B | 20.00% | 16.10% | 15.26% | 17.50% | 0.26 | 3.06 | 98.40% | 18.40% | 14.00% | ||
| TGTX | TG THERAPEUTICS INC | $4.43B | 26.10% | 9.60% | 18.37% | 16.60% | 1.54 | 3.86 | 87.00% | 13.30% | 21.47% | ||
| CRMD | CORMEDIX INC | $885.79M | 22.60% | 17.00% | 14.95% | 53.00% | 0.30 | 4.21 | 95.20% | 20.80% | 20.85% | ||
| GYRE | GYRE THERAPEUTICS INC | $725.24M | 5.80% | 3.10% | 5.16% | 7.40% | 0.25 | 5.40 | 95.90% | 4.10% | 6.85% | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $2.46B | 1.00% | 0.80% | 2.62% | 4.30% | 0.34 | 3.57 | 85.90% | 0.90% | 2.69% | ||
| KRYS | KRYSTAL BIOTECH INC | $4.17B | 15.20% | 13.80% | 16.05% | 26.50% | 0.09 | 9.68 | 93.40% | 40.80% | 46.98% | ||
| HALO | HALOZYME THERAPEUTICS INC | $8.19B | 136.60% | 26.40% | 36.99% | 27.90% | 5.17 | 8.36 | 84.20% | 47.30% | 60.25% | ||
| EXEL | EXELIXIS INC | $10.10B | 27.70% | 21.10% | 33.12% | 32.40% | 0.32 | 3.51 | 96.60% | 27.00% | 34.78% | ||
| RPRX | ROYALTY PHARMA PLC | $20.99B | 10.20% | 5.70% | 7.52% | 5.50% | 0.93 | 1.26 | 100.00% | 44.30% | 55.83% | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.58B | 16.70% | 11.50% | 15.80% | 14.50% | 0.50 | 5.23 | 89.50% | 23.30% | 25.77% | ||
| INVA | INNOVIVA INC | $1.29B | 5.70% | 3.00% | 7.86% | 9.00% | 0.87 | 2.64 | 86.60% | 10.40% | 23.09% | ||
| VCEL | VERICEL CORP | $1.83B | 2.50% | 1.70% | 2.00% | 2.00% | 0.42 | 4.97 | 73.50% | 2.90% | 3.16% | ||
| ARGX | ARGENX SE | $40.09B | 24.70% | 21.40% | 10.88% | 20.20% | 0.18 | 5.60 | -19,733.10% | 78,552.00% | 40,946.87% | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.09B | 26.30% | 17.70% | 25.99% | 53.80% | 0.43 | 3.84 | 78.30% | 23.40% | 31.22% | ||
| INCY | INCYTE CORP | $16.69B | 24.10% | 15.80% | 27.84% | 62.90% | 0.40 | 2.85 | 92.90% | 19.00% | 27.59% | ||
| ADMA | ADMA BIOLOGICS INC | $4.16B | 61.80% | 42.90% | 32.10% | 37.00% | 0.40 | 5.33 | 53.00% | 44.10% | 32.73% | ||
| MNKD | MANNKIND CORP | $1.22B | -32.60% | 7.80% | 22.86% | 11.40% | -8.48 | 2.50 | 74.90% | 10.90% | 22.71% | ||
| ATRA | ATARA BIOTHERAPEUTICS INC | $80.62M | -8.30% | 6.60% | 44.55% | 25.20% | -2.05 | 1.70 | 81.20% | 3.10% | 5.27% | ||
| MDXG | MIMEDX GROUP INC | $1.06B | 16.20% | 12.00% | 17.68% | 40.40% | 0.34 | 4.39 | 81.50% | 8.80% | 11.70% | ||
| TECH | BIO-TECHNE CORP | $8.60B | 6.30% | 4.90% | 7.22% | 13.40% | 0.31 | 3.71 | 65.80% | 10.90% | 14.79% | ||
| VCYT | VERACYTE INC | $2.32B | 2.80% | 2.60% | 2.83% | 23.70% | 0.10 | 5.10 | 68.00% | 7.10% | 7.57% | ||
| NVO | NOVO NORDISK A S | $244.59B | 77.90% | 24.20% | 51.26% | 67.90% | 1.87 | 0.78 | 83.90% | 35.60% | 45.13% | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.00B | 11.50% | 9.20% | 12.57% | 15.10% | 0.24 | 5.56 | 79.60% | 21.50% | 27.78% | ||
| NAGE | NIAGEN BIOSCIENCE INC | $768.02M | 35.50% | 23.80% | 26.49% | 199.80% | 0.43 | 3.88 | 63.60% | 15.20% | 15.76% | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.48B | 27.50% | 23.80% | 31.66% | 413.50% | 0.14 | 6.71 | 85.80% | 37.40% | 48.70% | ||
| GMAB | GENMAB A | $15.28B | 24.70% | 19.90% | 30.06% | 75.00% | 0.22 | 6.22 | 94.40% | 37.60% | 52.88% | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $100.19B | 22.10% | 15.90% | 22.07% | 31.10% | 0.40 | 2.52 | 86.10% | 31.90% | 38.45% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.